| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_aa2d1d961c591358634835e5743acd06 |
| classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12Q2600-156
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12Q2600-172
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12Q2600-106 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P25-28
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12Q1-6883 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-554
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12Q1-68
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D491-10 |
| filingDate |
2004-07-12-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_dfb5a488bc2d5b5e072f6feec8cdb3cc
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_68062e1c86bd563c8a331e26b1b60255
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_5586c6abb9d640cc2aa9ecae1fa84aa8
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_f03a3201b378050ccbce4b9412889141
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_9bdfaaac30f77df72d9e39e179e28806
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_36b90d6bcf2f58f44f05cf00b00259d6
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_1667ffd366ab3589cca79fa6dcd3c895
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_646b2401966c9a46eab275497cc3440d
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_f023620ef1a099f65d3fe90fb0e9a5f4 |
| publicationDate |
2005-03-10-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
CA-2531768-A1 |
| titleOfInvention |
Chrna2 genetic markers associated with galantamine response |
| abstract |
Haplotypes in the CHRNA2 gene associated with cognitive response to galantamine treatment are disclosed. Compositions and methods for detecting and using these CHRNA2 hyplotypes in a variety of clinical applications are disclosed. Such applications include articles of a manufacture comprising galantamine or derivatives thereof that are approved for treating patients having one of these CHRNA2 haplotypes, methods and kits for predicting the response of an individual to galantamine based upon his/her haplotype profile, and methods for treating Alzheimer~s patients based upon their haplotype profile. |
| priorityDate |
2003-07-11-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |